HS
BCYC

HighVista Strategies’s Bicycle Therapeutics BCYC Stock Holding History

HighVista Strategies’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-124,430
Closed -$1.74M – 151
2024
Q4 		$1.74M Sell
124,430
-15,114
-11% -$324K 0.65% 51
2024
Q3 		$3.16M Buy
139,544
+12,289
+10% +$283K 1.09% 25
2024
Q2 		$2.58M Sell
127,255
-31,038
-20% -$701K 0.94% 31
2024
Q1 		$3.94M Hold
158,293
– – 1.41% 16
2023
Q4 		$2.86M Buy
158,293
+65,859
+71% +$1.09M 1.04% 31
2023
Q3 		$1.86M Hold
92,434
– – 0.86% 38
2023
Q2 		$2.36M Hold
92,434
– – 1.08% 31
2023
Q1 		$1.97M Hold
92,434
– – 1.6% 24
2022
Q4 		$2.74M Sell
92,434
-44,325
-32% -$1.19M 1.62% 17
2022
Q3 		$3.18M Sell
136,759
-14,448
-10% -$344K 1.82% 16
2022
Q2 		$2.54M Buy
151,207
+132,909
+726% +$2.8M 1.53% 20
2022
Q1 		$803K Buy
+18,298
New +$854K 0.51% 57

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

HighVista Strategies's BCYC Position: Q1 2025 in Review

HighVista Strategies sold out of Bicycle Therapeutics (BCYC) in Q1 2025, closing a stake of 124,430 shares — an estimated $1.74M sold.

HighVista Strategies first reported a position in BCYC in Q1 2022 and held it in 12 quarters. The position peaked at $3.94M in Q1 2024. 95 funds tracked by Wall St. Rank hold BCYC as of Q1 2025.

  • HighVista Strategies reported no remaining Bicycle Therapeutics position as of Q1 2025 after selling out during the quarter.
  • HighVista Strategies sold 124,430 Bicycle Therapeutics shares in Q1 2025, an estimated $1.74M.
  • HighVista Strategies first reported a position in Bicycle Therapeutics in Q1 2022 and held it in 12 quarters.
  • HighVista Strategies's Bicycle Therapeutics position peaked at $3.94M in Q1 2024.
  • 95 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q1 2025.

Based on HighVista Strategies's 13F filing for Q1 2025, filed 15 May 2025.